Locations:
Search IconSearch
September 16, 2024/Neurosciences/Podcast

Temporal Lobe Epilepsy and the Potential of Gene Therapy (Podcast)

Investigational gene approaches offer hope for a therapeutically challenging condition

Despite recent therapeutic advances, about 30% of epilepsy cases remain pharmacoresistant. Among these medically intractable epilepsy cases, those involving temporal lobe epilepsy are among the most difficult to treat.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Temporal lobe epilepsy, particularly mesial temporal lobe epilepsy due to hippocampal sclerosis, was one of the first targets of surgical treatment for epilepsy,” says Imad Najm, MD, Director of the Epilepsy Center at Cleveland Clinic. “Yet even under the best conditions at the most experienced centers, treatment success with resective surgery for mesial temporal lobe epilepsy remains around 60% to 65%. Even though we often think of mesial temporal lobe epilepsy as unilateral, in many of the unsuccessful surgical cases seizures come back from the other side, and we cannot do surgery on both sides.”

In the latest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Najm offers context on the challenges of these highly refractory cases of temporal lobe epilepsy and emerging efforts to overcome them with gene therapy. He covers the following topics, among others:

  • Why temporal lobe epilepsy with hippocampal sclerosis is so therapeutically challenging
  • Why complete seizure control is essential to optimize patient safety
  • Considerations around when to refer patients for epilepsy surgery
  • How to approach weaning of antiseizure medications following epilepsy surgery
  • Neuromodulation and other therapy options when epilepsy surgery fails
  • The current landscape of gene therapies to treat temporal lobe epilepsy
  • Various methods for overcoming the blood-brain barrier to deliver gene therapy for epilepsy

Click the podcast player above to listen to the 30-minute episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Advertisement

This activity has been approved for AMA PRA Category 1 Credit™ and ANCC contact hours. After listening to the podcast, you can claim your credit here.

Excerpt from the podcast

Imad Najm, MD: The cancer field is about 20 years ahead of epilepsy when it comes to gene therapy. That’s because mutations have been found in some cancers that are very focal and very particular for the pathologies being treated. In epilepsy, most patients do not have a single pathological gene mutation. We have more studies showing something that we call polygenic changes, or multiple genes showing multiple mutations. None of these are pathological on their own, but collectively it seems like they increase the risk of epilepsy development.

Because of that, gene therapy in the context of focal epilepsies and even generalized epilepsies has not begun to catch up until recently. Over the past 10 to 15 years, we have started to see what we call somatic gene mutations in some focal pathologies in the brain, such as focal malformation of cortical development, or focal cortical dysplasia. These mutations are very much focal or restricted to the pathology, and these genes are part of pathways that are essential for axonogenesis, neurogenesis and synaptogenesis in epilepsy, as well as the plasticity and long-term potentiation leading to excitotoxicity.

These pathways seem to be significantly activated in focal cortical dysplasias, leading potentially to transformation of a pro-epileptic pathology to an active epilepsy focus. Although we cannot verify this 100% yet, there are some supportive preclinical models. This gives us hope that perhaps if we can target multiple genes at multiple levels of these pathways, we may be able to develop something to control these issues.

Advertisement

Related Articles

scalp EEG electrodes on a woman's head
October 17, 2024/Neurosciences/Epilepsy
Machine Learning Algorithm May Enhance Accuracy of Predicting Seizure Control After Epilepsy Surgery

Model relies on analysis of peri-ictal scalp EEG data, promising wide applicability

CQD-CHP4445460-hanna-sickle-650×450
January 30, 2024/Cancer
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival

William Clifton, MD, against a decorative background
November 4, 2024/Neurosciences/Podcast
Adult Idiopathic Scoliosis: Essentials of Diagnosis and Treatment (Podcast)

Early intervention yields the best outcomes, but surgery can benefit older patients as well

Creative illustration of a brain
October 16, 2024/Neurosciences/Podcast
Diagnosing Atypical Parkinsonian Disorders (Podcast)

Patient history plays a key role in identifying the condition

dr. daniel ontaneda against a decorative background
October 2, 2024/Neurosciences/Podcast
Takeaways From the New Diagnostic Criteria for Multiple Sclerosis (Podcast)

A co-author explains some of the key McDonald criteria revisions

alison stout, DO, against a decorative backdrop
August 9, 2024/Neurosciences/Podcast
Evaluation and Interventional Treatment of Axial Lumbar Back Pain (Podcast)

This common condition remains tough to work up and diagnose, and treatment options are limited

Dr. Amy Kunchok against decorative background
July 16, 2024/Neurosciences/Podcast
What to Know About Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) (Podcast)

It’s time to get familiar with this emerging demyelinating disorder

receptor activity for myasthenia gravis medications
July 3, 2024/Neurosciences/Podcast
Myasthenia Gravis: Unmet Needs and Efforts to Address Them (Podcast)

An overview of associated antibodies, therapies for antibody-positive disease and the outlook for atypical forms of MG

Ad